You are here: Industry Insights > Alzheimer

News List

Alzheimer's Drug Cuts Hallmark Inflammation Related to Metabolic Syndrome 25 Percent americanpharmaceuticalreview
July 21, 2017
In a study released today in JCI Insight, Feinstein Institute researchers found that the FDA-approved Alzheimer's drug "galantamine" cut key markers of inflammation
27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next 5 years worldpharmanews
July 21, 2017
according to a revised Alzheimer's pipeline analysis presented at the Alzheimer's Association International Conference (AAIC) by ResearchersAgainstAlzheimer's (RA2)
Alzheimer's and Parkinson's spurred by same enzyme worldpharmanews
July 06, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.
Alzheimer's and Parkinson's spurred by same enzyme worldpharmanews
July 06, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.
Alzheimer's, Parkinson's, and Huntington's diseases share common crucial feature worldpharmanews
May 27, 2017
A Loyola University Chicago study has found that abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease all share a similar ability to cause damage when they invade brain cells.
Singapore eDevelopment subsidiary starts advanced research on Linebacker pharmaceutical-technology
May 27, 2017
Singapore eDevelopment subsidiary Global BioLife has started advanced research on a new universal therapeutic drug platform called Linebacker to tackle multiple conditions such as Alzheimer's, diabetes, and cancer.
Which is to become the savior of Alzheimer’s disease? cphi.cn
May 18, 2017
Alzheimer’s disease (AD), commonly known as senile dementia, is a degenerative central nervous system (CNS) disease that has an insidious onset, with the clinical symptom mainly of neuropsychiatric symptoms...
Cuba looks to begin trials of new neuroprotective treatment for Alzheimer’s pharmafile
May 16, 2017
The health care system in Cuba is widely held up to be a model of innovation; despite severe economic sanctions for much of its recent history, it has kept up with ‘developed nations’ medical standards, as well as surpassing them in some areas.
Alzheimer’s experts call for changes in FDA drug approval standards europeanpharmaceuticalreview
May 15, 2017
Leading Alzheimer’s disease researchers and a prominent patient advocate today published an analysis, Single Endpoint for New Drug Approvals for Alzheimer’s Disease...
Rowan, Rutgers Announce Launch of Alzheimer’s Journey Coordinator Certificate Program americanpharmaceuticalreview
May 12, 2017
Rowan University/Rutgers-Camden Board of Governors (RURCBOG) announced a collaboration with Otsuka America Pharmaceutical and its affiliate Avanir Pharmaceuticals to launch an Alzheimer’s Journey Coordination Certificate Program.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page